Nanoscope in the News
-
Retina Synthesis: Optogenetics Interview with Samarendra Mohanty, PhD and Charles Wykoff, MD
May 3, 2022 by Nanoscope Therapeutics
-
Healio: Gene therapy platform for Stargardt macular degeneration receives IND clearance
January 25, 2022 by Nanoscope Therapeutics
-
Ophthalmology Times: Nanoscope Therapeutics announces FDA clearance of IND for MCO-010 gene therapy in Stargardt patients
January 25, 2022 by Nanoscope Therapeutics
-
Photonics West BIOS Show Daily: Optogenetics a Promising Route to Vision Restoration
January 22, 2022 by Nanoscope Therapeutics
-
Ft Worth Business Press: TechFW Client Nanoscope Receives $1.5M Grant to Move Macular Degeneration Therapy Forward
September 21, 2021 by Nanoscope Therapeutics
-
Dallas Innovates: Nanoscope Awarded $1.5 Million Grant for Eyesight Gene Therapy as it ‘Takes Steps to Go Public’
September 17, 2021 by Nanoscope Therapeutics
-
Journal of Cellular and Molecular Medicine: Biodistribution of adeno-associated virus type 2 carrying multi-characteristic opsin in dogs following intravitreal injection
August 23, 2021 by Nanoscope Therapeutics
-
The Science Advisory Board: Optogenetic gene therapy provides hope for retinitis pigmentosa patients
August 6, 2021 by Nanoscope Therapeutics
-
Fort Worth Business Press: First patient receives innovative gene therapy eye treatment from TechFW client
August 4, 2021 by Nanoscope Therapeutics
-
Retina Today: AAV Gene Therapy Trials to Watch
August 3, 2021 by Nanoscope Therapeutics
-
BIO.org: The Pandemic Highlights Need for More Women Scientists
July 28, 2021 by Nanoscope Therapeutics
-
Modern Retina: Optogenetic Gene Trial Begins, First Patient Dosed
July 28, 2021 by Nanoscope Therapeutics
-
Ophthalmology Times: First patient dosed in optogenetic gene therapy trial
July 19, 2021 by Nanoscope Therapeutics
-
Fighting Blindness Foundation: Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
July 19, 2021 by Nanoscope Therapeutics
-
Fort Worth Inc.: Bedford’s Nanoscope Begins Human Trial of Drug for Retinitis Pigmentosa
July 19, 2021 by Nanoscope Therapeutics
-
BioSpace: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b Clinical Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with RP
June 24, 2021 by Nanoscope Therapeutics
-
Ft. Worth Business Press: Nanoscope Therapeutics cleared to open Phase 2b clinical trial for vision therapy
June 23, 2021 by Nanoscope Therapeutics
-
Dallas Morning News: Bedford biotech’s eyesight-restoring gene therapy received FDA approval to test in the U.S.
June 23, 2021 by Nanoscope Therapeutics
-
Dallas Innovates: Bedford Biotech Restores “Meaningful Vision” in Blind Patients With Gene Therapy—and May Soon Go Public
June 22, 2021 by Nanoscope Therapeutics
-
Forbes: What is ‘Optogenetics’? Behind the Technology That’s Bringing Sight to The Blind.
June 16, 2021 by Nanoscope Therapeutics